|
市场调查报告书
肺癌治疗用抗体:开发平台，策略，临床
Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical
|
肺癌治疗用抗体:开发平台，策略，临床 是由出版商BioPharm Reports (Technology and Markets Ltd)在2011年10月所出版的。
这份英文市场调查报告书包含126 Pages 价格从美金1200起跳。
肺癌是全球最多人得的癌症，2008年有160万件新的肺癌病例，有140万人因肺癌而死亡(癌症的整体死亡人数大致上为20％)。与其他的癌症相比，5年存活率很低，美国的肺癌成本在全部的癌症中是第三高，间接成本也比其他癌症高。
本报告提供肺癌治疗用抗体市场相关整体分析，把肺癌治疗作为主要适用的研究开发与临床开发趋势等汇整数据，为您概述为以下内容。
摘要整理
第1章 背景
- 肺癌
- 统计
- 诊断
- 肺癌的分期
- 肺癌治疗
- 存活率
- 肺癌成本
- 新的开发
- 本报告
- 参考
第2章 已通过核准及后期阶段的治疗用抗体
第3章 早期阶段治疗用抗体
- 简介
- 概要
- 第二阶段疫苗
- 第1/2阶段疫苗
- 第一阶段疫苗
- 前临床阶段疫苗
- 参考
第4章 其他的候选治疗药物
- 简介
- 概要
- 免疫活化剂:第二阶段
- 抗体共轭:第1/2阶段
- 双特异性抗体:第一阶段
- 抗体共轭:第一阶段
- 免疫刺激剂:第一阶段
- 抗体共轭:第一阶段
- 参考
第5章 考察
- 背景
- 开发平台
- 治疗用抗体
- 其他的候选治疗药物
- 企业
- 治疗标靶
- 治疗方法
- 参考
图表
Abstract
This report provides a comprehensive review of 27 candidate therapeutic
antibodies that are being evaluated for the treatment of lung cancer; covering
pipeline, disease-targeting strategies and clinical findings. These antibodies
are directed at 17 potential targets.
Globally, lung cancer is the most common cancer and in 2008 there were an
estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all
cancer deaths) caused by this disease. Five-year survival rates are also low
(15-20%) compared to other common cancers. In the US, studies have shown that
lung cancer-care costs (in 2006) were the third highest of all cancers, while
indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of lung cancer on society drive the
development of new therapies. While improvements have been seen in diagnosis
and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new
therapies that build on the capabilities of existing approaches, are urgently
required
Today, developments continue to be made in drug treatments for lung cancer; in
chemotherapy, new drug combinations, and targeted molecules. In particular,
advances are being seen in the field of immunotherapy; in the development of
new therapeutic antibodies and therapeutic vaccines.
This Report
This report provides a comprehensive review of lung cancer
therapeutic antibodies and reviews R&D and clinical developments in the
treatment of lung cancer as the primary indication, as well as studies that
are evaluating lung cancer alongside other cancers.
Today, more than 25 candidate therapeutic antibodies are in development or are
being evaluated for the treatment of lung cancer, most of which are already in
clinical trials. This field is also showing substantial innovation and these
molecules are being directed at 17 different targets. This report gives an
overview of the status and clinical findings of these candidate vaccines,
together with developmental and market-related perspectives in this field.
Key content:
- Late-stage (Phases 2/3, 3 and Approved, n = 4) pipeline therapeutic
antibodies and companies
- Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) pipeline
therapeutic antibodies and companies
- Other (mainly antibody related, n=6) candidate therapies in the
development pipeline for targeting lung cancer, Phase 1, 1/2 and 2
- Drug targets being targeted by therapeutic antibodies from preclinical
through to Phase 3, and Approved
- Descriptions of clinical trials (patients and numbers, conditions,
treatments, regimens, Phase 1-3) of therapeutic antibodies being evaluated for
the treatment of lung cancer
- Summaries of clinical status and clinical findings (safety, adverse events
and multiple event-related clinical responses) reported following clinical
trials (Phase 1-3) of therapeutic antibodies being evaluated for the treatment
of lung cancer
- Commercial partnerships and collaborations on pipeline therapeutic
antibodies
- Drug combination strategies in the evaluation of therapeutic antibodies
for the targeting of lung cancer
- A comprehensive listing of salient details of clinical trials of
therapeutic antibodies being evaluated for the treatment of lung cancer
- Technical and market insights and perspectives in the development and
clinical evaluation of therapeutic antibodies for the treatment of lung cancer
- Competitive and market-related information
Table of Contents
Executive Summary
Chapter 1 - Background
- 1. Lung Cancer
- 1.1. Statistics
- 1.2. Diagnosis
- 1.3. Lung Cancer Staging
- 1.4. Treatment of Lung Cancer
- 1.5. Survival Rates
- 1.6. Cost of Lung Cancer
- 1.7. New Developments
- 1.8. This Report
Chapter 2 - Approved and Late-Stage Therapeutic Antibodies
- Summary
- 2.1. Introduction
- 2.2. Overview
- 2.3. (One antibody, Approved)
- 2.4. - 2.6. (Three antibodies, Phase 3)
Chapter 3 - Early-Stage Therapeutic Antibodies
- 3.1. Introduction
- 3.2. Overview
- 3.3. - 4.12. (Ten antibodies, Phase 2)
- 3.13. - 4.18. (Six antibodies, Phase 1/2)
- 3.19. - 4.23. (Five antibodies, Phase 1)
- 4.24. - 4.25. (Two antibodies, Preclinical)
Chapter 4 - Other Candidate Therapies
- Summary
- 4.1. Introduction
- 4.2. Overview
- 4.3. (One Immune Activator, Phase 2)
- 4.4. (One Antibody Conjugate, Phase 1/2)
- 4.5. (One Bispecific Antibody, Phase 1)
- 4.6. (One Antibody Conjugate, Phase 1)
- 4.7. (One Immune Stimulant, Phase 1)
- 4.8. (One Antibody Conjugate, Phase 1)
Chapter 5 - Discussion
- 5.1. Background
- 5.2. Pipeline
- 5.3. Therapeutic Antibodies
- 5.4. Other Candidate Therapies
- 5.5. Companies
- 5.6. Therapeutic Targets
- 5.7. Therapeutic Approaches
Tables
- 1.1. Global incidence and mortality from lung cancer, 2008
- 1.2. NSCLC survival rates, according to cancer stage
- 1.3a. Five-year relative cancer survival rates in the USA for white males
- 1.3b. Five-year relative cancer survival rates in the USA for white females
- 1.4. US national expenditure on different cancers (2006)
- 1.5. US lost productivity due to different cancer types in the US, 2005
- 2.1. Approved/late-stage candidate therapeutic antibodies for the
treatment of lung cancer
- 3.1. Early-stage therapeutic antibodies being developed or evaluated for
the treatment of lung cancer or for lung cancer/other cancers
- 4.1. Other (largely antibody-related) therapies being developed or
evaluated for the treatment of lung cancer or lung cancer/other cancers
- 5.1. Approved/late-stage therapeutic antibodies being developed for the
treatment of lung cancer
- 5.2. Early-stage candidate therapeutic antibodies being developed or
evaluated for the treatment of lung cancer or for lung cancer/other cancers
- 5.3. Other (primarily antibody-related) therapies in development or being
evaluated for lung cancer or for lung cancer/other cancers
- 5.4. Approved/candidate therapeutic antibodies for the treatment of lung
cancer or for lung cancer/other cancers
- 5.5. Other candidate therapies (primarily antibody-related) for the
treatment of lung cancer or for lung cancer/other cancers
- 5.6. NSCLC survival rates, according to cancer stage
Figures
- 3.1. Early-stage pipeline therapeutic antibodies for the treatment of lung
cancer or lung cancer/other cancers
- 5.4. Approved and pipeline therapeutic antibodies being developed or
evaluated for the treatment of lung cancer or for lung/other cancers
- 5.6. Other (primarily antibody-related) early-stage candidate therapies in
development or being evaluated for lung cancer or for lung cancer/other cancers
- 5.10. Organisations developing or evaluating lung cancer therapeutic
antibodies
- 5.12. Clinical trials of therapeutic antibodies for the treatment of lung
cancer or lung cancer/other cancers, involving single or combination agents
|
